Evidence map›Paper›PMID 42733589›Full record

ArticleBioactive materials2027

An oral coral-like resveratrol nanocomplex protects against dry eye disease through ocular and systemic redox homeostasis.

Qingchen Cui, Yaqiong Li, Mengzhen Xie, Ziyu Liu, Yihan Guo, Yunxiao Zang, Jiayu Bao, Qianru Wu, Lei Tian, Ying Jie

Abstract read
In one paragraph

Article in Bioactive materials, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qingchen CuiBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijing, 100005, China.
Yaqiong LiBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijing, 100005, China.
Mengzhen XieBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijing, 100005, China.
Ziyu LiuBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijing, 100005, China.
Yihan GuoBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijing, 100005, China.
Yunxiao ZangBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijing, 100005, China.
Jiayu BaoBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijing, 100005, China.
Qianru WuBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijing, 100005, China.
Lei TianBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijing, 100005, China.
Ying JieBeijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing Tongren Hospital, Capital Medical University, Beijing, 100005, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dry eye disease (DED) is a progressive ocular disorder in which chronic inflammation and oxidative stress synergistically damage ocular tissues and impair vision. While topical anti-inflammatory and artificial tears therapies are the standard treatment for DED, their long-term application is limited by adverse effects and poor patient compliance. Emerging evidence suggests that systemic redox dysregulation contributes to DED pathogenesis, highlighting the potential of oral antioxidant intervention as a disease-modifying strategy. However, the clinical translation of oral antioxidants has been constrained by poor bioavailability and rapid metabolic clearance. Herein, a coral-like resveratrol nanocomplex was fabricated with a composite natural carrier of sericin and dipotassium glycyrrhizinate through a simple pH-ultrasonic-shifting method in aqueous solution, enabling effective oral delivery of this potent polyphenolic antioxidant. This coral-like nanocomplex markedly enhanced gastrointestinal stability and systemic exposure of resveratrol, increasing oral bioavailability by approximately 6.62-fold and ocular accumulation by 2.49-fold. The nanocomplex exerted robust ocular and systemic antioxidant effects and protected against experimental DED in mice. Oral administration of this nanocomplex protected against benzalkonium chloride (BAC)-induced corneal epithelial damage, tear film dysfunction, and inflammatory responses. Mechanistically, the nanocomplex alleviated oxidative damage through ocular and systemic redox homeostasis. Rather than acting solely on the ocular surface, this orally nanomedicine may provide complementary therapeutic benefits through ocular and systemic redox regulation, while also being associated with modulation of gut microbiota and metabolic profiles. These findings support oral redox intervention as a promising complementary strategy for protecting against the DED, particularly for reducing the burden of prolonged topical treatment.

Indexed as

AntioxidantDry eye diseaseNanocomplexOral bioavailabilityResveratrolSystemic redox homeostasis

Identifiers

PMID42733589
PMCPMC13571528

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.